Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Anticounterfeiting Technology Guide Aims To Speed Industry Adoption

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency will exercise enforcement discretion on labeling and GMP regulations that are triggered by radio frequency identification technology. FDA is working with EPC Global to establish standards of electronic pedigree.

You may also be interested in...



Radio Frequency ID Technology Cannot Substitute For Bar Coding, FDA Says

Exemptions from bar coding requirements will not be granted for products with a low frequency of medication errors or small containers, FDA says in a draft guidance clarifying its bar coding final rule. Labelers – not distributors – will be responsible for bar code rule compliance.

Radio Frequency ID Technology Cannot Substitute For Bar Coding, FDA Says

Exemptions from bar coding requirements will not be granted for products with a low frequency of medication errors or small containers, FDA says in a draft guidance clarifying its bar coding final rule. Labelers – not distributors – will be responsible for bar code rule compliance.

FDA Studying Effects Of Radio-Frequency ID Technology On Liquid Drugs

The agency has seen "tremendous progress" in the move toward electronic product codes and use of radio-frequency identification, FDA says in its annual counterfeit drug update. FDA initiated 58 counterfeit drug investigations in 2004, up from 30 the previous year.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS058124

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel